Showing results (371-380 of 431) with videos related to
Sort By:
Pageof 44
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancerI Craig Henderson, Donald A Berry, George D Demetri, et al.Pharmacogenomics|August 24, 2023
Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226Delaney V Rutherford, Sarah Medley, Nicholas C Henderson, et al.Journal of the National Cancer Institute|March 5, 2026
Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancerYashasvini Sampathkumar, Ziad Zakaria, Kelli O'Connell, et al.International Journal of Cancer|November 28, 2025
Evaluation of methods to identify chemotherapy-related hematologic toxicities in real-world settingsPeng Wang, Kelli O'Connell, Jenna Bhimani, et al.Cancer|February 24, 2026
Initial chemotherapy dose reductions and subsequent treatment delivery in stage I-IIIA breast cancerMaria J Monroy-Iglesias, Kelli O'Connell, Jenna Bhimani, et al.The Surgical Clinics of North America|July 24, 2003
Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging ManualS Eva Singletary, Craig Allred, Pandora Ashley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2002
Revision of the American Joint Committee on Cancer staging system for breast cancerS Eva Singletary, Craig Allred, Pandora Ashley, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019Costanza Paoletti, Yufeng Li, Maria C Muñiz, et al.The Lancet. Oncology|January 9, 2023
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trialEve Rodler, Priyanka Sharma, William E Barlow, et al.Journal of Translational Medicine|July 4, 2012
Considerations in the development of circulating tumor cell technology for clinical useDavid R Parkinson, Nicholas Dracopoli, Brenda Gumbs Petty, et al.Pageof 44